Phase II clinical development of new drugs

著者

書誌事項

Phase II clinical development of new drugs

Naitee Ting ... [et al.]

(ICSA book series in statistics / series editors, Jiahua Chen, Ding-Geng (Din) Chen)

Springer, c2017

大学図書館所蔵 件 / 1

この図書・雑誌をさがす

注記

Other authors: Ding-Geng Chen, Shuyen Ho, Joseph C. Cappelleri

Includes bibliographical references and index

内容説明・目次

内容説明

This book focuses on how to appropriately plan and develop a Phase II program, and how to design Phase II clinical trials and analyze their data. It provides a comprehensive overview of the entire drug development process and highlights key questions that need to be addressed for the successful execution of Phase II, so as to increase its success in Phase III and for drug approval. Lastly it warns project team members of the common potential pitfalls and offers tips on how to avoid them.

目次

Chapter 1 Introduction.- Chapter 2 Concept of Alpha.- Chapter 3 Confirmation and Exploration.- Chapter 4 Design a Proof of Concept (PoC) Trial.- Chapter 5 Design of Dose-Ranging Trials.- Chapter 6 Combining PoC and Dose Ranging Trials.- Chapter 7 Risks of Inconclusiveness.- Chapter 8 Analysis of a PoC Study.- Chapter 9 Data Analysis for Dose-Ranging Trials with Continuous Outcome.- Chapter 10 Data Analysis of Dose-Ranging Trials for Binary Outcomes.- Chapter 11 Bayesian Methods.- Chapter 12 Overview of Phase III Clinical Trials.

「Nielsen BookData」 より

関連文献: 1件中  1-1を表示

詳細情報

  • NII書誌ID(NCID)
    BB23589925
  • ISBN
    • 9789811041921
  • LCCN
    2017934053
  • 出版国コード
    si
  • タイトル言語コード
    eng
  • 本文言語コード
    eng
  • 出版地
    Singapore
  • ページ数/冊数
    xvii, 241 p.
  • 大きさ
    25 cm
  • 親書誌ID
ページトップへ